FR2774590A1 - COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING A PLANT EXTRACT OBTAINED FROM BACOPA MONNIERI (L.) - Google Patents
COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING A PLANT EXTRACT OBTAINED FROM BACOPA MONNIERI (L.) Download PDFInfo
- Publication number
- FR2774590A1 FR2774590A1 FR9801873A FR9801873A FR2774590A1 FR 2774590 A1 FR2774590 A1 FR 2774590A1 FR 9801873 A FR9801873 A FR 9801873A FR 9801873 A FR9801873 A FR 9801873A FR 2774590 A1 FR2774590 A1 FR 2774590A1
- Authority
- FR
- France
- Prior art keywords
- extract
- cosmetic
- bacopa monnieri
- bacopa
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015418 Bacopa monnieria Nutrition 0.000 title claims abstract description 39
- 240000002999 Bacopa monnieri Species 0.000 title claims abstract description 32
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 239000000419 plant extract Substances 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 230000035882 stress Effects 0.000 claims description 9
- 241000295198 Bacopa Species 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- -1 cyclic polyols Chemical class 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000004098 cellular respiration Effects 0.000 claims description 3
- 230000004089 microcirculation Effects 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 108010004103 Chylomicrons Proteins 0.000 claims description 2
- 208000001840 Dandruff Diseases 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 230000003656 anti-hair-loss Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 claims description 2
- 235000012216 bentonite Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002803 maceration Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 210000004761 scalp Anatomy 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000003255 anti-acne Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000000874 microwave-assisted extraction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000002137 ultrasound extraction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000037075 skin appearance Effects 0.000 abstract 1
- 230000004215 skin function Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 18
- 238000012360 testing method Methods 0.000 description 12
- 239000008267 milk Substances 0.000 description 8
- 208000035824 paresthesia Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000002366 lipolytic effect Effects 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229930193652 Bacoside Natural products 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Le mode de vie actuel impose des agressions de toutes sortes, physiques, chimiques et psychologiques aux organismes qui y sont soumis. La peau constituant la seule interface entre l'individu et le monde extérieur, il est clair que cet organe est le premier élément corporel atteint par les agressions physiques et chimiques extérieures produits par la pollution en général et spécialement par la pollution atmosphérique. Le stress psychologique quant à lui se répercute au niveau cutané par deux voies différentes:
D'une part, le stress psychique a des répercussions directement physiologiques. La peau subit des altérations dues aux déséquilibres induits par les brusques variations des taux d'hormones circulantes, en réponses aux différentes séquences du stress quotidien. Ces brusques variations modifient au niveau intime des cellules, cutanées et autres, les régulations biochimiques, délicates et fines, qui assurent la pérennité d'un organisme. Bien que non localisée au niveau cutané, la conséquence la plus connue de ce type de stress est l'ulcère de l'estomac.The current way of life imposes aggressions of all kinds, physical, chemical and psychological on the organisms which are subjected to it. The skin constituting the only interface between the individual and the outside world, it is clear that this organ is the first bodily element reached by the physical and chemical external aggressions produced by pollution in general and especially by atmospheric pollution. Psychological stress, on the other hand, affects the skin in two different ways:
On the one hand, mental stress has direct physiological repercussions. The skin undergoes alterations due to imbalances induced by sudden variations in the levels of circulating hormones, in response to the different sequences of daily stress. These sudden variations modify at the intimate level of cells, skin and others, the biochemical regulations, delicate and fine, which ensure the sustainability of an organism. Although not localized in the skin, the best known consequence of this type of stress is stomach ulcer.
D'autre part, pour faire face aux stress psychiques, les individus ont de plus en plus recours à des palliatifs comme par exemple, l'alimentation déséquilibrée qui va du simple désordre quotidien à la boulimie ou à l'anorexie, le tabac, l'alcool, voire à utiliser des produits antidépresseurs. Les conséquences néfastes des consommations excessives de tabac et d'alcool sont bien connues au niveau cutané: couperose, dessèchement et vieillissement prématuré en sont trois des principales caractéristiques.On the other hand, to cope with mental stress, individuals are increasingly resorting to palliative measures such as, for example, unbalanced diet which ranges from simple daily disorder to bulimia or anorexia, tobacco, l alcohol, or even to use antidepressant products. The harmful consequences of excessive tobacco and alcohol consumption are well known at the cutaneous level: rosacea, dryness and premature aging are three of the main characteristics.
Ces agressions sont permanentes et il est quasiment impossible de s'y soustraire de manière continue et efficace.These attacks are permanent and it is almost impossible to escape them continuously and effectively.
Il est alors dans la logique des industries Cosmétiques et Dermo-pharmaceutiques de mettre au point des produits qui aident la peau à mieux supporter, voire à corriger et/ou à réparer, les conséquences néfastes de ces diverses agressions.It is therefore in the logic of the Cosmetics and Dermo-pharmaceutical industries to develop products that help the skin to better withstand, or even correct and / or repair, the harmful consequences of these various attacks.
La Bacopa est une plante aquatique et lacustre comptant environ une centaines d'espèces différentes et qui se développe dans les régions les plus chaudes du monde. La Bacopa monnieri L. se développe principalement en Chine, dans les provinces de Guangdong et de
Yunnan par exemple, ainsi qu'à Taiwan. Récemment, la Bacopa monnieri L. a été importée avec succès en Califomie du Sud.Bacopa is an aquatic and lakeside plant with about a hundred different species and which grows in the warmest regions of the world. Bacopa monnieri L. develops mainly in China, in the provinces of Guangdong and
Yunnan for example, as well as in Taiwan. Recently, Bacopa monnieri L. has been successfully imported into Southern Califomy.
Des extraits grossiers de cette plante étaient utilisés dans la médecine traditionnelle hindoue pour le traitement des retards du développement intellectuel ainsi que dans ceux des désordres mentaux tels que de l'épilepsie et la démence (Nadkarni KM, 1954,1:p624). Plus récemment, des études in vitro on montré une activité anticancéreuse de Bacopa monnieri (par exemple: Bhakuni DS et al., 1969,3,p24; Elangovan V et al.,1995,55:21 1-215). Coarse extracts of this plant were used in traditional Hindu medicine for the treatment of retarded intellectual development as well as in mental disorders such as epilepsy and dementia (Nadkarni KM, 1954,1: p624). More recently, in vitro studies have shown anti-cancer activity of Bacopa monnieri (for example: Bhakuni DS et al., 1969,3, p24; Elangovan V et al., 1995,55: 21 1-215).
Nous avons découvert que, convenablement réalisés, les extraits de Bacopa monnieri possèdent aussi des effets bénéfiques lorsqu'ils sont appliqués par voie topique.We have discovered that, when properly made, Bacopa monnieri extracts also have beneficial effects when applied topically.
L'invention faisant l'objet de ce présent brevet, réside dans la découverte qu'un extrait végétal obtenu à partir de Bacopa monnieri, est capable de protéger la peau des effets des différents stress évoqués ci-dessus, par des propriétés apaisantes, hydratantes, régulatrices de la microcirculation et de la respiration cellulaire et également d'activation de la lipolyse.The invention which is the subject of this present patent resides in the discovery that a plant extract obtained from Bacopa monnieri, is capable of protecting the skin from the effects of the various stresses mentioned above, by soothing and hydrating properties. , regulating microcirculation and cellular respiration and also activating lipolysis.
L'extrait végétal est obtenu par le traitement, dans un rapport de 100 grammes de Bacopa monnieri pour 1 litre d'éthanol, pendant 48 heures à température ambiante. Après séchage, l'extrait sec obtenu est repris dans de l'eau.The plant extract is obtained by treatment, in a ratio of 100 grams of Bacopa monnieri per 1 liter of ethanol, for 48 hours at room temperature. After drying, the dry extract obtained is taken up in water.
Cet exemple d'obtention de l'extrait végétal du Bacopa, n'est pas limitatif.This example of obtaining the plant extract of Bacopa, is not limiting.
Il est en effet possible de réaliser l'extrait de Bacopa monnieri par d'autres procédés comme, par exemple, la macération, la simple décoction, la lixiviation, l'extraction sous reflux, l'extraction au moyen d'ultrasons ou de micro-ondes ou enfin des techniques à contre courant, sans que cette liste soit limitative.It is indeed possible to produce the extract of Bacopa monnieri by other processes such as, for example, maceration, simple decoction, leaching, extraction under reflux, extraction by means of ultrasound or micro -waves or finally techniques against the current, without this list being exhaustive.
Par ailleurs, les solvants d'extraction cités ci-dessus ne sont pas limitatifs et peuvent être choisis parmi l'eau, le propylène glycol, le butylène glycol, la glycérine, le polyéthylène glycol, les éthers méthyliques ou éthyliques des diglycols, les polyols cycliques, les diglycols éthoxylés ou propoxylés, les alcools (méthanol, propanol, butanol), ou tout mélange de ces solvants.Furthermore, the extraction solvents mentioned above are not limiting and can be chosen from water, propylene glycol, butylene glycol, glycerin, polyethylene glycol, methyl or ethyl ethers of diglycols, polyols cyclic, ethoxylated or propoxylated diglycols, alcohols (methanol, propanol, butanol), or any mixture of these solvents.
L'analyse par chromatographie liquide haute pression (HPLC) de l'extrait de Bacopa monnieri révèle la présence de différents composés de type glycoside pseudojujubojenine et, plus particulièrement de Bacosides A et B.Analysis by high pressure liquid chromatography (HPLC) of the extract of Bacopa monnieri reveals the presence of various compounds of the glycoside pseudojujubojenine type, and more particularly of Bacosides A and B.
Bien qu'il ne soit pas limitatif, l'exemple suivant illustrera une utilisation possible de l'extrait végétal obtenu à partir de Bacopa monnieri dans une composition cosmétique ou dermopharmaceutique:
Lait corporel
Polysorbate 60 2,5
Acide oléique 0,9
Huile de lanoline 2,5
Carbopol 940 0,3
Cire d'abeille 2,0
Triéthanolamine 0,1
Glycérine 5,0
Extrait de Bacopa monnieri 3,0
Eau & conservateurs QSP 100g
Parmi les divers effets bénéfiques trouvés au cours du développement de l'extrait végétal de
Bacopa monnieri décrit précédemment, trois tests d'efficacité seront mentionnés.Although it is not limiting, the following example will illustrate a possible use of the plant extract obtained from Bacopa monnieri in a cosmetic or dermopharmaceutical composition:
Body lotion
Polysorbate 60 2.5
Oleic acid 0.9
Lanolin oil 2.5
Carbopol 940 0.3
Beeswax 2.0
Triethanolamine 0.1
Glycerin 5.0
Bacopa monnieri 3.0 extract
Water & preservatives QSP 100g
Among the various beneficial effects found during the development of the plant extract
Bacopa monnieri described above, three efficacy tests will be mentioned.
Le premier qui est un test ex-vivo consiste à exposer une peau reconstituée à différents stress. La peau reconstituée, consiste en une couche dermique sur laquelle sont apposés de kératinocytes qui vont former un épiderme multicouches, différencié et semblable à la peau normale. Cette méthode est une méthode alternative de référence en Cosmétique et en
Dermopharmacie puisqu'elle permet de tester des produits par une méthode in vitro mais dans les conditions très proches de l'in vivo.The first which is an ex-vivo test consists in exposing a reconstituted skin to different stresses. The reconstituted skin consists of a dermal layer on which are affixed keratinocytes which will form a multilayer epidermis, differentiated and similar to normal skin. This method is an alternative benchmark method in Cosmetics and
Dermopharmacy since it makes it possible to test products by an in vitro method but under conditions very close to in vivo.
Au moyen de ce système, nous avons testé le pouvoir régénérant cellulaire (antistress et réparateur) après une agression chimique réalisée avec une solution de triéthanolamine à 30%. Le lait corporel a été testé en comparaison de la même composition réalisée sans extrait de Bacopa monnieri (lait placebo).Using this system, we tested the cell regenerating power (anti-stress and repair) after a chemical attack carried out with a 30% triethanolamine solution. Body milk was tested in comparison with the same composition made without Bacopa monnieri extract (placebo milk).
Le test de régénération cellulaire consiste à appliquer une solution de triéthanolamine (30%), pendant 30 minutes, sur la peau équivalente puis, de la rincer plusieurs fois avec de l'eau déminéralisée. Les produits à tester sont alors appliqués pendant deux heures, laps de temps au bout duquel le nombre de cellules survivantes est mesuré au moyen du colorant fluorescent Hoechst 3348. Dans ces conditions, en présence du lait contenant l'extrait de
Bacopa monnieri, il est possible de conclure qu'en présence de l'extrait de Bacopa monnieri, le nombre de cellules vivantes après l'agression chimique est supérieur d'environ 36% qu'en son absence.The cell regeneration test consists in applying a solution of triethanolamine (30%), for 30 minutes, to the equivalent skin and then rinsing it several times with demineralized water. The products to be tested are then applied for two hours, after which time the number of surviving cells is measured using the fluorescent dye Hoechst 3348. Under these conditions, in the presence of milk containing the extract of
Bacopa monnieri, it is possible to conclude that in the presence of the extract of Bacopa monnieri, the number of living cells after chemical attack is approximately 36% higher than in its absence.
Le second test réalisé, connu sous le nom de "Stinging Test", est un test in vivo classiquement utilisé pour mettre en évidence des propriétés apaisantes au niveau cutané de produits cosmétiques ou dermopharmaceutiques et peut être décrit comme suit.The second test carried out, known as the "Stinging Test", is an in vivo test conventionally used to demonstrate soothing properties on the skin of cosmetic or dermopharmaceutical products and can be described as follows.
Une solution à 10% d'acide lactique dans du sérum physiologique est appliquée au niveau de chacun des deux sillons nasogéniens. Les sensations de picotements sont évaluées par le volontaire, immédiatement après l'application, au niveau des deux sillons, par un système de cotation bien défini (aucun picotement=0; légers=1; modérés=2; importants=3).A 10% solution of lactic acid in physiological saline is applied to each of the two nasolabial folds. The tingling sensations are evaluated by the volunteer, immediately after application, at the level of the two furrows, by a well-defined rating system (no tingling = 0; slight = 1; moderate = 2; significant = 3).
Le lait corporel dont la composition a été donnée précédemment comme exemple d'utilisation, contenant 3 % d'extrait de Bacopa monnieri est appliqué tel quel, en une seule fois, dès l'apparition des picotements, du côté du nez préalablement choisi de manière randomisée par l'investigateur. Dans le même temps, l'autre coté reçoit le placebo (même composition si ce n'est l'absence d'extrait de Bacopa monnieri). L'intensité des picotements est relevée au cours des 5 minutes suivant l'application, au niveau de la zone ayant reçu le placebo ou l'extrait de Bacopa monnieri, selon le même système de cotation que celui déterminé pour l'évaluation de la réactivité initiale. La totalité de l'essai est réalisée dans une pièce climatisée, dans laquelle la température ambiante et l'hygrométrie sont maintenues constantes.Body milk, the composition of which was given previously as an example of use, containing 3% of extract of Bacopa monnieri, is applied as it is, in one go, as soon as the tingling appears, on the side of the nose previously chosen so randomized by the investigator. At the same time, the other side receives the placebo (same composition except for the absence of Bacopa monnieri extract). The intensity of the tingling is noted during the 5 minutes following the application, in the area having received the placebo or the extract of Bacopa monnieri, according to the same rating system as that determined for the evaluation of the reactivity. initial. The entire test is carried out in an air-conditioned room, in which the ambient temperature and the humidity are kept constant.
L'intensité moyenne des picotements est déterminée à chaque temps de l'essai, par le calcul de la moyenne arithmétique et de l'écart par rapport à la moyenne (SEM) des données individuelles obtenues sur l'ensemble des volontaires.The average intensity of tingling is determined at each time of the test, by calculating the arithmetic mean and the deviation from the mean (SEM) of the individual data obtained on all the volunteers.
L'analyse des résultats a porté sur les valeurs obtenues au niveau de la zone traitée avec le produit étudié, en comparaison des valeurs acquises au niveau de la zone témoin ayant reçu l'acide lactique seul avant l'application du produit étudié ("temps 0"), pour chacune des zones traitée et témoin.The analysis of the results related to the values obtained in the area treated with the product studied, in comparison with the values acquired in the control area having received lactic acid alone before the application of the product studied ("time 0 "), for each of the treated and control zones.
Le test a été réalisé sur 20 volontaires, 15 femmes et de 5 hommes, âgés de 21 à 55 ans qui avaient tous la peau du visage définie comme étant "hypersensible", par la méthode du "Stinging Test".The test was carried out on 20 volunteers, 15 women and 5 men, aged 21 to 55 who all had facial skin defined as "hypersensitive", by the "Stinging Test" method.
L'analyse des résultats démontre que par rapport au placebo, le lait contenant l'extrait de
Bacopa monnieri entraîne une diminution significative de l'intensité des picotements, et cela, dès les 5 premières secondes d'application et durant les 5 minutes que dure l'essai.Analysis of the results shows that compared to placebo, the milk containing the extract of
Bacopa monnieri causes a significant decrease in the intensity of tingling, and this, from the first 5 seconds of application and during the 5 minutes that the test lasts.
Le lait corporel contenant l'extrait de Bacopa monnieri démontre donc clairement, au niveau cutané, un puissant effet apaisant vis-à-vis des picotements ressentis par les volontaires à la suite de l'agression chimique. Il est à noter que dans les mêmes conditions expérimentales, le lait corporel sans l'extrait de Bacopa monnieri (lait placebo) présente les mêmes scores que ceux observés habituellement sur des zones non traitées, ce qui démontre bien que c'est seulement à l'extrait de Bacopa monnieri précédemment décrit dans ce brevet que l'on peut attribuer l'effet bénéfique observé.The body milk containing the extract of Bacopa monnieri therefore clearly demonstrates, at the cutaneous level, a powerful soothing effect vis-à-vis the tingling sensations felt by the volunteers following the chemical attack. It should be noted that under the same experimental conditions, body milk without the extract of Bacopa monnieri (placebo milk) has the same scores as those usually observed in untreated areas, which clearly shows that it is only at Bacopa monnieri extract previously described in this patent can be attributed to the beneficial effect observed.
Un troisième exemple va démontrer, au moyen d'une étude in vitro, une autre activité de l'extrait de Bacopa monnieri qui consiste à stimuler la libération des acides gras et du glycérol à partir des triglycérides contenus dans les adipocytes.A third example will demonstrate, by means of an in vitro study, another activity of the extract of Bacopa monnieri which consists in stimulating the release of fatty acids and glycerol from the triglycerides contained in the adipocytes.
Des adipocytes humains (obtenus à partir de morceaux de peau prélevés lors de chirurgie plastique) sont mis en suspension dans un milieu de survie. Le métabolisme lipolytique de base est suivi par le dosage de glycérol et d'acides gras libérés dans le temps.Human adipocytes (obtained from pieces of skin removed during plastic surgery) are suspended in a survival medium. The basic lipolytic metabolism is followed by the dosage of glycerol and fatty acids released over time.
On ajoute ensuite différentes concentrations d'extraits préparés selon le procédé décrit précédemment ou un procédé similaire ; après un temps d'incubation plus ou moins long, on constate l'augmentation du métabolisme lipolytique par une augmentation de la quantité de glycérol et d'acides gras libérés dans le milieu. Un témoin positif de stimulation est constitué par la théophylline.Then added different concentrations of extracts prepared according to the method described above or a similar method; after a more or less long incubation time, there is an increase in lipolytic metabolism by an increase in the amount of glycerol and of fatty acids released in the medium. A positive stimulation control consists of theophylline.
Les résultats obtenus sont les suivants:
Augmentation du remariage de glycérol par rapport à la réponse témoin obtenue en présence du seul véhicule de l'extrait de Bacopa monnieri (placebo):
Extrait de Bacopa monnieri à 5 % 167 %
Théophylline 87 %
Ces exemples ne sont pas limitatifs. Selon le type de procédé d'extraction employé, la quantité de plante mise en jeu, la concentration d'extrait utilisée dans le milieu cellulaire, l'activité lipolytique peut varier de +10 à +1550%. Il s'avère que l'addition de caféine, de théophylline ou d'autres dérivés de xanthine potentialisent encore l'activité lipolytique.The results obtained are as follows:
Increase in glycerol remarriage compared to the control response obtained in the presence of the only vehicle of Bacopa monnieri extract (placebo):
Bacopa monnieri extract 5% 167%
Theophylline 87%
These examples are not limitative. Depending on the type of extraction process used, the amount of plant involved, the concentration of extract used in the cell environment, the lipolytic activity can vary from +10 to + 1550%. It turns out that the addition of caffeine, theophylline or other xanthine derivatives further potentiate lipolytic activity.
En même temps, on constate que ces extraits possèdent une activité in vivo (application topique) non seulement amincissante (mise en évidence par échographie aux ultrasons dans
R une étude clinique sur 20 personnes), mais également raffermissante. L'étude au CutométreR (Courage et Khazaka) permet de mesurer l'élasticité et la tonicité de la peau, d'où l'on peut déduire le paramètre "fermeté". On observe une augmentation significative de la fermeté de la peau à la suite d'un traitement prolongé avec les extraits de cette plante.At the same time, we find that these extracts have an in vivo activity (topical application) not only slimming (demonstrated by ultrasound ultrasound in
R a clinical study on 20 people), but also firming. The CutometreR study (Courage and Khazaka) measures the elasticity and tone of the skin, from which the "firmness" parameter can be deduced. There is a significant increase in the firmness of the skin following prolonged treatment with the extracts of this plant.
Les effets décrits ci-dessus étant donnés à titre d'exemple, il est possible de mentionner, sans que la liste suivante soit exhaustive, d'autres effets bénéfiques de l'extrait de Bacopa monnieri sur les conséquences cutanées néfastes induites par toutes situations de stress, comme, par exemple, des propriétés apaisantes, calmantes, relaxantes, hydratantes, régénérantes, régulatrices de la microcirculation et de la respiration cellulaire; propriétés qui sont nécessaires pour obtenir des effets anti-vieillissement, antiride, anti-inflammatoire, amincissant, sur le cuir chevelu (antipelliculaire et ou anti chute de cheveux), sur la peau acnéique et donc des effets qui prolongent la souplesse et la fonction protectrice de la peau.The effects described above being given by way of example, it is possible to mention, without the following list being exhaustive, other beneficial effects of the extract of Bacopa monnieri on the harmful skin consequences induced by all situations of stress, such as, for example, soothing, calming, relaxing, hydrating, regenerating properties, regulating microcirculation and cellular respiration; properties which are necessary to obtain anti-aging, anti-wrinkle, anti-inflammatory, slimming effects, on the scalp (anti-dandruff and or anti hair loss), on acne skin and therefore effects which prolong the suppleness and the protective function skin.
L'extrait végétal de Bacopa monnieri est utilisé soit sous forme liquide, soit sous forme sèche obtenue par les techniques classiques de précipitation, de séchage, d'évaporation, d'atomisation ou de lyophilisation
L'extrait végétal obtenu à partir de Bacopa précédemment décrit peut être utilisé dans toute forme galénique employée en Cosmétique ou Dermopharmacie: émulsions H/E et E/H, laits, lotions, pommades, lotions capillaires, shampooings, savons, sticks et crayons, sprays, huiles corporelles, sans que cette liste soit limitative.The plant extract of Bacopa monnieri is used either in liquid form or in dry form obtained by conventional techniques of precipitation, drying, evaporation, atomization or lyophilization
The plant extract obtained from Bacopa previously described can be used in any dosage form used in Cosmetics or Dermopharmacy: O / W and W / O emulsions, milks, lotions, ointments, hair lotions, shampoos, soaps, sticks and pencils, sprays, body oils, without this list being exhaustive.
Il est possible d'incorporer l'extrait végétal obtenu à partir de Bacopa précédemment décrit, dans des vecteurs cosmétiques tels que les liposomes, les chylomicrons, les macro-, micro- et nanoparticules ainsi que les macro-, micro- et nanocapsules; de l'absorber sur des polymères organiques poudreux, les talcs, bentonites et autres supports minéraux.It is possible to incorporate the plant extract obtained from Bacopa previously described, in cosmetic vectors such as liposomes, chylomicrons, macro-, micro- and nanoparticles as well as macro-, micro- and nanocapsules; absorb it on powdery organic polymers, talcs, bentonites and other mineral supports.
L'extrait végétal obtenu à partir de Bacopa précédemment décrit peut être combiné dans les compositions cosmétiques avec tout autre ingrédient habituellement utilisé en cosmétique: lipides d'extraction et/ou de synthèse, polymères gélifiants et viscosants, tensioactifs et émulsifiants, principes actifs hydro- ou liposolubles, extraits d'autres plantes, extraits tissulaires, extraits marins.The plant extract obtained from Bacopa previously described can be combined in cosmetic compositions with any other ingredient usually used in cosmetics: extraction and / or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifiers, hydro-active ingredients. or fat-soluble, extracts from other plants, tissue extracts, marine extracts.
Les concentrations de l'extrait végétal obtenu à partir de Bacopa précédemment décrit peuvent varier entre 0,01% et 40% (p/p), préférentiellement entre 0.5 % et 7 % en poids,Qans le produit fini. The concentrations of the plant extract obtained from Bacopa previously described can vary between 0.01% and 40% (w / w), preferably between 0.5% and 7% by weight, in the finished product.
Claims (10)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9801873A FR2774590B1 (en) | 1998-02-12 | 1998-02-12 | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING A PLANT EXTRACT OBTAINED FROM BACOPA MONNIERI (L.) |
| AU22836/99A AU2283699A (en) | 1998-02-12 | 1999-02-04 | Composition for cosmetic or dermopharmaceutical use containing a plant extract obtained from (bacopa monnieri (l.)) |
| PCT/FR1999/000245 WO1999040897A1 (en) | 1998-02-12 | 1999-02-04 | Composition for cosmetic or dermopharmaceutical use containing a plant extract obtained from bacopa monnieri (l.) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9801873A FR2774590B1 (en) | 1998-02-12 | 1998-02-12 | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING A PLANT EXTRACT OBTAINED FROM BACOPA MONNIERI (L.) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2774590A1 true FR2774590A1 (en) | 1999-08-13 |
| FR2774590B1 FR2774590B1 (en) | 2001-07-13 |
Family
ID=9523039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9801873A Expired - Lifetime FR2774590B1 (en) | 1998-02-12 | 1998-02-12 | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING A PLANT EXTRACT OBTAINED FROM BACOPA MONNIERI (L.) |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2283699A (en) |
| FR (1) | FR2774590B1 (en) |
| WO (1) | WO1999040897A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120027697A1 (en) * | 2010-03-23 | 2012-02-02 | Namita Deo | Plant extracts, compositions containing same, and uses thereof |
| US20150306164A1 (en) * | 2012-12-03 | 2015-10-29 | Soho Flordis International Pty Ltd | Uses of bacopa monnieri extract |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002003996A1 (en) * | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| WO2004060267A2 (en) * | 2003-01-03 | 2004-07-22 | Ganga Raju Gokaraju | A process for producing enriched fractions containing up to 100% of bacoside a and bacoside b |
| CN1893911B (en) | 2003-11-17 | 2010-12-29 | 赛德玛公司 | Formulations containing a mixture of tetrapeptides and tripeptides |
| FR2890310B1 (en) | 2005-09-06 | 2009-04-03 | Sederma Soc Par Actions Simpli | USE OF PROTOBERBERINS AS AGENTS REGULATING THE ACTIVITY OF THE PILOSEBACEE UNIT |
| ES2638242T3 (en) | 2006-02-16 | 2017-10-19 | Sederma | KXK polypeptides and their use |
| FR2900573B1 (en) | 2006-05-05 | 2014-05-16 | Sederma Sa | NOVEL COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE PEPTIDE CONTAINING AT LEAST ONE BLOCKED AROMATIC CYCLE |
| WO2007142096A1 (en) * | 2006-06-02 | 2007-12-13 | Organo Corporation | Inhibitor of inducible nitric oxide synthase, beverage/food, and neutraceutical food |
| FR2939799B1 (en) | 2008-12-11 | 2011-03-11 | Sederma Sa | COSMETIC COMPOSITION COMPRISING ACETYL OLIGOGLUCURONANS. |
| EP3744729B1 (en) | 2009-01-16 | 2023-03-01 | Sederma | Peptides, compositions comprising them and cosmetic and dermopharmaceutical uses |
| FR2941232B1 (en) | 2009-01-16 | 2014-08-08 | Sederma Sa | NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES |
| FR2941231B1 (en) | 2009-01-16 | 2016-04-01 | Sederma Sa | NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES |
| FR2944435B1 (en) | 2009-04-17 | 2011-05-27 | Sederma Sa | COSMETIC COMPOSITION COMPRISING ORIDONIN |
| FR2945939B1 (en) | 2009-05-26 | 2011-07-15 | Sederma Sa | COSMETIC USE OF TYR-ARG DIPEPTIDE TO FIGHT SKIN RELEASE. |
| FR2955326B1 (en) | 2010-01-18 | 2015-01-02 | Sederma Sa | NOVEL LIPO-PHOSPHATE OR LIPO-SULFATE COMPOUND, COMPOSITIONS CONTAINING SAME AND COSMETIC AND DERMOPHARMACEUTICAL USES |
| FR2958641B1 (en) | 2010-04-08 | 2014-12-26 | Sederma Sa | NOVEL POLYTERPENIC COMPOUNDS, COSMETIC, NUTRACEUTICAL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF. |
| FR2958541B1 (en) | 2010-04-08 | 2012-05-18 | Sederma Sa | COSMETIC USE OF GERANYLGERANYL-2-PROPANOL |
| CN110101625A (en) * | 2019-06-14 | 2019-08-09 | 芳香世家化妆品(广州)有限公司 | A kind of nutrition restorative facial cream |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0358939A (en) * | 1989-07-27 | 1991-03-14 | Toreede Uindo Kk | Aging preventive food agent and production thereof |
| EP0717983A1 (en) * | 1994-12-20 | 1996-06-26 | Unilever Plc | Cosmetic compositions containing betulinic acid |
| GB2314269A (en) * | 1996-06-21 | 1997-12-24 | M S Raptakos Brett & Co Ltd | Anti-AIDS Ayurvedic medicine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19654635C1 (en) * | 1996-12-28 | 1998-01-08 | Singh Verma Shyam B | Cosmetic containing Phyllanthus emblica and Centella asiatica extract |
-
1998
- 1998-02-12 FR FR9801873A patent/FR2774590B1/en not_active Expired - Lifetime
-
1999
- 1999-02-04 WO PCT/FR1999/000245 patent/WO1999040897A1/en not_active Ceased
- 1999-02-04 AU AU22836/99A patent/AU2283699A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0358939A (en) * | 1989-07-27 | 1991-03-14 | Toreede Uindo Kk | Aging preventive food agent and production thereof |
| EP0717983A1 (en) * | 1994-12-20 | 1996-06-26 | Unilever Plc | Cosmetic compositions containing betulinic acid |
| GB2314269A (en) * | 1996-06-21 | 1997-12-24 | M S Raptakos Brett & Co Ltd | Anti-AIDS Ayurvedic medicine |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE NAPRALERT Bd. Trustees, U. Il.; 1941, N. N. SIRCAR: "Identification of Brahmi", XP002081244 * |
| I. BROWN: "Constituents of Bacopa monnieri", J. CHEM. SOC., 1960, pages 2783 - 2784, XP002081243 * |
| PATENT ABSTRACTS OF JAPAN vol. 015, no. 206 (C - 0835) 27 May 1991 (1991-05-27) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120027697A1 (en) * | 2010-03-23 | 2012-02-02 | Namita Deo | Plant extracts, compositions containing same, and uses thereof |
| US20150306164A1 (en) * | 2012-12-03 | 2015-10-29 | Soho Flordis International Pty Ltd | Uses of bacopa monnieri extract |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2283699A (en) | 1999-08-30 |
| WO1999040897A1 (en) | 1999-08-19 |
| FR2774590B1 (en) | 2001-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2771002A1 (en) | Compositions containing Kava Piper methysticum root extract | |
| FR2774590A1 (en) | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING A PLANT EXTRACT OBTAINED FROM BACOPA MONNIERI (L.) | |
| WO1999018927A1 (en) | Compositions for cosmetic and dermopharmaceutical use containing a plant extract obtained from clover (trifolium sp.) | |
| EP0797985A1 (en) | Use of an extract of iridaceas in the treatment of skin wrinkles | |
| EP3054963B1 (en) | Cosmetic or dermatological use of an extract of hamamelis virginiana leaves | |
| FR2985424A1 (en) | NEW TOPICAL USE OF ZERUMBON | |
| CA3164351A1 (en) | Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses | |
| EP0946138B1 (en) | Use of a potentilla erecta extract in the cosmetic and pharmaceutical field | |
| FR2973230A1 (en) | USE OF GINGERONE OR ITS DERIVATIVES TO DECREASE OR DELAY THE SIGNS OF SKIN AGING | |
| FR2865652A1 (en) | USE OF PLANT EXTRACTS AND PURIFIED MOLECULES FOR LIPOLYTICALLY SLIMMING, COSMETIC, NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITIONS. | |
| FR2880278A1 (en) | USE OF OIL AND PROTEINS EXTRACTED FROM PLUKENETIA VOLUBILIS LINNEO SEEDS IN COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL PREPARATIONS | |
| KR101208013B1 (en) | A skin-care agent containing mycoleptodonoides aitchisonii mycelium extract | |
| WO2015036704A1 (en) | Cosmetic or dermatological use of an extract of tapirira guianensis | |
| FR3061013A1 (en) | COMPOSITION COMPRISING DIGENEASIDE, PROCESS FOR OBTAINING SAME AND COSMETIC, VETERINARY OR NUTRACEUTICAL USE | |
| FR3110426A1 (en) | New extract of roses for cosmetic use | |
| WO2002047653A2 (en) | Cosmetic or dermo-pharmaceutical compositions containing four o'clock (mirabilis jalapa) plant extracts | |
| FR3008890B1 (en) | OAK EXTRACT, COMPOSITION COMPRISING SAID EXTRACT AND USES IN PARTICULAR COSMETICS | |
| FR3152405A1 (en) | COSMETIC USE OF A ROSA GALLICA EXTRACT | |
| FR3110416A1 (en) | Ylang-ylang absolute for use as a cosmetic active | |
| FR3139466A1 (en) | Use of a Sichuan pepper extract for skin treatment and a composition adapted to this use. | |
| EP1620185A2 (en) | Cosmetic or pharmaceutical composition comprising amino acids, use and dermatological treatment methods | |
| FR2871380A1 (en) | Topical cosmetic and/or dermatological composition, used to fight against signs of cutaneous ageing and to prevent/treat uncontrolled facial muscular contractions, comprises blue lotus extract | |
| FR3010307A1 (en) | COSMETIC OR DERMATOLOGICAL USE OF AVICULARIN | |
| FR3029789A1 (en) | USE OF A PAPAVER EXTRACT AND COMPOSITION PERMITTING SAID USE | |
| FR3156041A1 (en) | Use of Osmanthus fragrans extract for cosmetic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 19 |
|
| PLFP | Fee payment |
Year of fee payment: 20 |